NATCO Pharma soars on launching Carboplatin Injection
Natco Pharma is currently trading at Rs. 800.90, up by 15.65 points or 1.99% from its previous closing of Rs. 785.25 on the BSE.
The scrip opened at Rs. 784.20 and has touched a high and low of Rs. 809.75 and Rs. 778.75 respectively. So far 57598 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1216.20 on 12-May-2026 and a 52 week low of Rs. 780.75 on 19-Oct-2026.
Last one week high and low of the scrip stood at Rs. 809.75 and Rs. 778.75 respectively. The current market cap of the company is Rs. 15574.75 crore.
The promoters holding in the company stood at 49.39%, while Institutions and Non-Institutions held 22.15% and 28.46% respectively.
NATCO Pharma has launched Carboplatin Injection, a generic version of Paraplatin in the U.S. market by its U.S. subsidiary NATCO Pharma USA LLC. The company launches this product in manufacturing collaboration with Teyro Labs, based in Chennai. This launch helps address a critical shortage of the product in the U.S. market.
Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. Carboplatin Injection had estimated sales of $27.8 million in the U.S. for 12 months ending June 2026 as per industry sales data.
